World News
JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective when continued for 2 years, results from a phase III trial extension indicated.
Some 85% of patients remained…



:max_bytes(150000):strip_icc()/healthiest-breads-11857140-final-346c95d2b66b4e969f12b92e4a7cdc00.jpg?w=390&resize=390,220&ssl=1)